Skip to content

    Dr. Reddy's Laboratories Limited

    DRREDDY
    Healthcare·23 Jul 2025
    Management Summary

    Dr. Reddy's Laboratories reported a mixed Q1 FY26, with consolidated revenues growing 11% YoY to ₹8,545 crores, despite a 17% decline in US generics. EBITDA margin of 26.7% exceeded the 25% aspiration, though it saw YoY compression due to gross margin pressure and increased SG&A investments. The company made progress in strategic areas like biosimilars and NRT integration, while addressing recent USFDA observations at its Srikakulam facility.

    Highlights

    5
    • Consolidated revenues of ₹8,545 crores ($997 million) grew 11% YoY, driven by steady performance across most markets.

    • EBITDA margin stood at 26.7%, modestly ahead of the aspiration of 25%.

    • Closed the quarter with a net cash surplus of $341 million, reinforcing a strong balance sheet position.

    • Biosimilars business gained momentum through a strategic collaboration with Alvotech for pembrolizumab.

    • India business reported ₹1,471 crores in Q1, delivering 11% YoY growth and outperforming the IPM.

    Concerns

    5
    • US generics business declined 17% YoY to $400 million, primarily due to price erosion in Lenalidomide and procurement timing.

    • Gross profit margin decreased 350 bps YoY to 56.9% due to price erosion and lower operating leverage.

    • SG&A spend increased 13% YoY, reaching 30% of sales, driven by strategic growth-oriented investments.

    • EBITDA margin decreased 149 bps YoY and 243 bps QoQ to 26.7%.

    • Srikakulam FTO-11 formulations facility received 7 observations in a USFDA GMP and Pre-Approval Inspection.

    What Changed3

    vs Q2 FY26

    Guidance items4 → 14 (+10)Risks discussed5 → 3 (-2)Q&A highlights5 → 8 (+3)

    Key financials

    Single quarter

    10 metrics
    1. 01Consolidated Revenues₹8,545 Cr+11%YoY
    2. 02Gross Profit Margin56.9%-3.5%YoY
    3. 03SG&A Spend₹2,565 Cr+13%YoY
    4. 04R&D Spend₹624 Cr0%YoY
    5. 05EBITDA₹2,278 Cr+5%YoY

    Segment breakdown

    North America Generics
    400 Mn Revenues
    European Generics
    131 Mn Revenues
    Emerging Markets
    ₹1,404 Cr Revenues
    India
    ₹1,471 Cr Revenues
    PSAI
    95 Mn Revenues
    List

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    ₹683 crores this quarter · ₹2,500 crores (FY26) planned

    Debt

    0.5x EBITDA

    M&A

    Alvotech (for pembrolizumab)

    joint venture · signed

    M&A

    NRT business

    acquisition · integrated

    Liquidity

    Cash ₹2,922 crores

    Guidance & targets

    14
    CategoryTargetPriority
    Margin
    R&D Spend as % of Sales
    7-7.5%
    High
    Margin
    SG&A Spend as % of Sales
    28-29%
    High
    Margin
    Discretionary Cost Adjustment (R&D, SG&A)
    500-600 basis points
    Medium
    Tax
    Normalized Effective Tax Rate
    around 25%
    High
    Product Launch
    Semaglutide Launch (Canada)
    Beginning of January 2026
    High
    Product Launch
    Semaglutide Launch (RoW)
    87 markets
    High
    Product Launch
    Abatacept IV Formulation Launch
    December '26 or January '27
    High
    Product Launch
    Abatacept Subcutaneous Formulation Launch
    A year later than IV formulation
    High
    Capacity
    Semaglutide Pen Capacity (Partner)
    10 million pens
    High
    Capacity
    Semaglutide Pen Capacity (Partner)
    12 million pens
    High
    Revenue
    CDMO Business Sales
    $100 million
    High
    Revenue
    CDMO Business Sales
    $250-300 million
    High
    Growth
    India Business Growth
    consistent double-digit growth
    High
    Market Share
    India Market Position
    number 5
    High

    Srikakulam FTO-11 Facility USFDA Status

    next quarter
    CurrentForm 483 with 7 observations
    TargetVAI (Voluntary Action Indicated)

    Why it matters

    Resolution of regulatory observations is crucial for continued operations and new product approvals from this facility.

    Last week, the USFDA conducted a GMP and Pre-Approval Inspection at our FTO-11 formulations facility in Srikakulam, Andhra Pradesh, resulting in a Form 483 with seven observations. We will respond within the required timelines.

    How to verify

    risks_and_concerns[risk='Srikakulam FTO-11 Facility USFDA Observations'].management_stance

    Risks & concerns

    3
    RiskSeverity

    US Generics Price Erosion

    Price erosion in select products, particularly Lenalidomide, contributed to a 17% YoY decline in US generics revenue and a 350 bps YoY decrease in gross profit margin.Management acknowledged

    high

    Srikakulam FTO-11 Facility USFDA Observations

    USFDA inspection resulted in a Form 483 with seven observations; management expects a VAI classification after responding.Management acknowledged

    medium

    Semaglutide Patent/IP Hurdles (India)

    Ongoing patent litigation in Delhi High Court for Semaglutide in India, though management believes it will not stop the Canadian launch and expects a satisfactory outcome.Analyst downplayed

    medium

    Q&A highlights

    8

    “Overall, the base business, the way I see, it's going to be flat to a single digit growth... Most of the decline that you see Q-on-Q was attributed to Lenalidomide... what you should anticipate is one more quarter, give or take, in the range of what you have today, and relatively much less in Q3. And after that some left over, and that's it.”

    Clarifies the impact and expected phase-out timeline of Lenalidomide, a key driver of US generics decline, and provides an outlook for the base business.

    asked by Amey Chalke

    2 min read5 chapters

    Detailed Narrative

    01

    Q1 FY26 Financial Performance Overview

    Dr. Reddy's reported consolidated revenues of ₹8,545 crores ($997 million) for Q1 FY26, marking an 11% year-on-year growth but remaining flat sequentially. The EBITDA margin stood at 26.7%, slightly exceeding the company's aspiration of 25%, despite a 149 basis points year-on-year and 243 basis points quarter-on-quarter decline. This margin compression was primarily attributed to a 350 basis points YoY decrease in gross profit margin, driven by price erosion in generics, particularly Lenalidomide, and lower operating leverage. Profit after tax attributable to equity holders grew 2% YoY to ₹1,419 crores ($166 million).

    02

    Segmental Business Performance

    The US generics business faced headwinds, declining 17% YoY to $400 million, mainly due to price erosion in Lenalidomide and timing of📎 procurement. In contrast, European generics revenues surged 124% YoY to €131 million, boosted by contributions from the acquired Nicotine Replacement Therapy (NRT) portfolio and new product launches. Emerging Markets grew 10% YoY to ₹1,404 crores, with Russia contributing a 17% YoY increase. The India business also delivered robust growth of 11% YoY to ₹1,471 crores, outperforming the Indian Pharmaceutical Market.

    03

    Strategic Investments and Pipeline Progress

    The company continues to make targeted R&D investments, which were ₹624 crores (7.3% of sales) this quarter, focusing on complex generics, API, and biosimilars. Key pipeline assets like Semaglutide and Abatacept are progressing, with Semaglutide's Canadian launch targeted for January 2026 and Abatacept's Phase III readout expected in November 2025. The biosimilars portfolio was strengthened by a strategic collaboration with Alvotech for the co-development, manufacture, and commercialization of pembrolizumab. The CDMO business is projected to achieve $100 million in sales for FY26 and $250-300 million by 2030.

    04

    Regulatory and Operational Updates

    During the quarter, the USFDA inspected the Middleburgh API facility and Miryalaguda API facility, both receiving two Form 483 observations, which have since been addressed or are being responded to. More recently, the FTO-11 formulations facility in Srikakulam received seven Form 483 observations, for which the company expects a VAI classification. The phased integration of the acquired NRT business is proceeding as planned, with additional markets like Canada, Australia, and Western Europe being onboarded.

    05

    Capital Allocation and Outlook

    Dr. Reddy's reported a net cash surplus of ₹2,922 crores ($341 million) and a Capex cash outflow of ₹683 crores ($80 million) for the quarter. The full-year Capex is projected to be between ₹2,500-₹2,700 crores, with significant allocation to peptides and biosimilars. Management aims to maintain SG&A at 28-29% of sales for the full year, down from 30% in Q1, and expects a normalized effective tax rate of around 25%. The company also indicated a maximum net debt to EBITDA ratio of 0.5.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.